48 Different chromatin accessibility in murine male and female inner cell mass
E. Ruggeri A , E. Grow B , X. Liu A , A. Donjacour A and P. Rinaudo AA University of California San Francisco, UCSF, San Francisco, CA, USA;
B Huntsman Cancer Institute, Cairns Research Laboratory, University of Utah, Salt Lake City, UT, USA
Reproduction, Fertility and Development 31(1) 150-150 https://doi.org/10.1071/RDv31n1Ab48
Published online: 3 December 2018
Abstract
Previous research has shown that embryos conceived by IVF show a sexual dimorphic phenotype and different metabolite expression into adulthood. Interestingly, female embryos have a higher apoptotic rate and are more vulnerable to environmental stressors. Our prior studies have examined DNA methylation changes in male and female embryos; however, limited knowledge is available with regard to chromatin accessibility in male and female embryos. The objective of this study was to assess if genome-wide chromatin accessibility changes occur in the inner cell mass (ICM) of the male v. female mouse embryo. For this experiment we utilised expanded blastocysts (CF-1 females × B6D2F1 males) that were obtained by IVF or flushed out of the uterus (FB, control). We performed IVF using KSOM with amino acids and 5% O2. The ICM were isolated from trophectoderm cells utilising immunosurgery and complement. The chromatin status was assessed using an assay for transposase-accessible chromatin status using a sequencing (ATAC seq) protocol modified from Wu et al. (2016 Nature 524, 652-657, DOI: 10.1038/nature18606). Briefly, cells were lysed and nuclei incubated with the Tn5 transposome and tagmentation buffer (Nextera, Illumina Inc., San Diego, CA, USA). After tagmentation, PCR amplification (15 cycles), mitochondrial depletion, and library purification were performed. The sex of the embryo was determined based on MSY (male sex region on the Y chromosome) and total Y chromosome aligning reads. Samples were then divided into 2 groups, male (n = 20) and female (n = 25), and sequencing was completed using Illumina HiSEqn 2500 (Illumina Inc.). Sequencing was completed using Illumina HiSEqn 2500. MACS2 (